HPVC2016-108 Biopharmaceutical - Infliximab

Current Contract

Contract Start Date
01 Feb 2016
Contract End Date
30 Apr 2022
Option Periods
Nil

Description

For the provision of Biopharmaceutical Infliximab

Additional Information

Update: 15 October 2021

 HPVC2016-108 Biopharmaceutical – Infliximab

 HSV is currently engaging with the incumbent contract holders, Janssen-Cilag and Pfizer to review contract pricing with consideration for contract extension to 30 April 2024

 

 

Contract Details

The Principal Period commenced on 1st of February 2016 and ran until 30th of April 2018.

The first Contract Option period of two years was executed – effective from 1 May 2018 until 30 April 2020.

The second Contract Option of two years has been executed – effective from 1 May 2020 until 30 April 2022.

Option Periods Remaining

Nil

Sales Report Template

https://www.hpv.org.au/documents/details/164
(You must be a registered supplier on the HPV website and have logged in to access the link above for the new reporting template.)